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(Hons), MPhil, PhD, Olivia M. Dean, BSc, PhD, Seetol Dodd, BSc, DipEd, MSc, PhD,
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ABSTRACT
N-acetyl cysteine (NAC) is a widely available
nutraceutical with a variety of actions. As a pre-
cursor of cysteine and glutathione, it has anti-
oxidant properties that may impact on mood
and contribute to an effect on impulsivity and
obsessive behaviour. Via its additional effect on
glutamate via the cystine-glutamate exchange
system, NAC has been shown to mediate impul-
sivity in preclinical models of addiction, reduce
craving, and cue extinction. Further, by boost-
ing glutathione, NAC acts as a potent anti-
oxidant and has been shown in two positive,
large-scale randomized placebo-controlled trials
to affect negative symptoms in schizophrenia
and depression in bipolar disorder. We describe
three cases in which its actions specifically on
nail-biting and associated anxiety may offer a
potential treatment. The spontaneous findings
are reported as part of an ongoing treatment
trial examining the utility of NAC in bipolar dis-
order. Its actions, if robustly replicated, also
point to potential treatment targets in glutathi-
one or glutamate pathways in the brain.
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INTRODUCTION
Many findings in psychopharmacology are
a result of clinical observation of serendipi-
tous findings; this pattern is repeated in this
case series. Pathological nail biting is a disor-
der that begins in adolescence and is regarded
as a disruption of normal grooming behav-
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ior. This behavior is regarded as being in the
compulsive-impulsive spectrum and is associ-
ated with psychological consequences includ-
ing reduced self-esteem, as well as localized
trauma and risk of infection.' There is minimal
data on the treatment of nail biting, with pre-
liminary research suggesting that serotonergic
agents may be of value, akin to other disorders
in that spectrum such as compulsive skin pick-
ing and trichotillomania.^
One safe and well-tolerated compound that
offers some promise as a potential treatment
in compulsive-impulsive disorders is N-acet-
ylcysteine (NAC).^  NAC is widely available as
a nutraceutical supplement and is an agent
with multiple properties. It has an antioxidant
action in its own right and influences neu-
trophil inhibition, antimicrobial attachment,
vasodilation, and mucolysis.^ For over half a
century it has been used therapeutically, tra-
ditionally as a mucolytic, in the treatment of
paracetamol poisoning and most recently as a
renal protectant."*
Thus far, five cases of réduction in groom-
ing disorders'(trichotillomania, skin picking, and
nailbiting) with NAC have been reported,^  with a
single case report describing its use in the treat-
ment refractory of obsessive-compulsive dis-
order.^ NAC has also been demonstrated to be
useful in other impulsivity related behaviours.
Grant and colleagues' gave open-labelled NAC
(600-1,800 mg/day) to 27 subjects with patho-
logical gambling, with 16 responders after 8
weeks of treatment. Studies by LaRowe and col-
leagues* and Mardikian and colleagues^ suggest
that NAC may be useful for the treatment of
cocaine addiction.
This case series describes a reduction in nail
biting reported spontaneously in the context of
a clinical trial of add-on NAC for the treatment of
bipolar disorder. It is noteworthy that nail-biting
was not a target of intervention in this trial and
no behavioural suggestions were given that nail-
biting, or related behaviors, may be impacted by
NAC treatment, reducing the likelihood of the
qbservations being a halo effect.
CASE 1
A 46-year-old woman was first diagnosed
with bipolar disorder following a suicide
attempt at 17 years of age. She had no further
problems until 34 years of age when her fourth
child was born with a disability. She was work-
ing two jobs and her marriage fell apart. Since
then she has been frequently depressed and
had psychotic episodes. Presently she takes 900
mg of lithium and 300 mg of quetiapine daily.
At the first follow-up visit of the trial, 2
weeks after commencing on NAC 1,000 mg
BID, she spontaneously reported that she had
"stopped biting her nails". Seven months
later, she has still not bitten them. Reviewing
her nail-biting history she describes herself
as a life long "nail biter" who has always had
great difficulty in ceasing the habit. At 10 years
of age her father offered her $1 for each nail
she could grow, but she was unable to grow
any. One month before her wedding, she did
manage to stop, however, her nails did not
grow much and were once again bitten off
soon afterwards. In the past if she occasionally
stopped nail biting for a short while her nails
remained very soft, and bent and broke eas-
ily, especially along the ridges that grew into
them. However on this occasion her nails have
regrown strong and do not have any ridges.
She stated that she had not consciously sought
to stop biting them and it just happened.
CASE 2
A 44-year-old woman with symptoms of
depression and anxiety for most of her life had
suffered many major life events including abuse
and violence between her parents and the deaths
of two sisters due to a rare genetic disease. At
38 years of age she was diagnosed with rapid
cycling bipolar disorder and put on a disabil-
ity pension. She had a keen interest in natural
therapies and took minimal medication. She was
on mirtazapine 15 mg, fish oil, zinc, magnesium,
vitamin B6, and valerian for sleeping.
Four months after starting on NAC 1,000 mg
BID, she reported that she had ceased nail biting
for the first time in a decade. Two months later,
she had not resumed nail-biting even though she
is a "lifelong nail biter", stating that everyone in
her family does it and has only ever managed
briefly to grow them for cosmetic reasons at 20
years of age. She is very aware ofthe link between
stress and nail biting. Since commencing on NAC
she has felt relaxed enough to consciously stop
biting them. She initially noticed that one nail had
grown and consequently focused on stopping bit-
ing the remainder.
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CASE 3
A 46-year-old man who had experienced
depressive and manic symptoms from 16 years
of age was first diagnosed with bipolar disor-
der at 45 years of age. In the past he had been
hospitalized three times for depression and had
tried medication but found the weight gain side
effects intolerable. He had a family history of
depression on his maternal side but none of his
immediate family had significant psychological
disorders. He also described obsessional think-
ing concerning exercise and diet, and had a
longstanding habit of chewing on his nails and
the surrounding skin of his fingers.
After participating in the NAC trial for 28 weeks
he reported that he had noticed a reduction in his
nail-biting behavior. He was not sure when his nail-
biting had begun to diminish as it had not been the
result of a conscious decision to alter his behavior.
DISCUSSION
NAC has two major mechanisms that mark
it as an agent of potential value in disorders in
the compulsive-impulsive spectrum. Firstly, glu-
tamate, and in particular the cystine-glutamate
exchange system, has been shown to mediate
impulsivity in preclinical models of addiction,
and NAC has been shown to reduce craving and
cue extinction in animal models of both cocaine
and opiate dependence.^" Secondly, NAC, by
boosting glutathione, is a potent antioxidant,
and has been shown in two positive, large-
scale randomized placebo-controlled trials"'^^ to
potentially affect substance use in schizophrenia
and in bipolar disorder. NAC's benefit on depres-
sion in bipolar disorder suggests that its role
in dysphoric mood states may positively affect
compulsive-impulsive behaviors.'"
The nucleus accumbens is a key region impli-
cated in impulsivity where basal levels of extra-
cellular glutamate are maintained primarily by
the exchange of extracellular cysteine for intracel-
lular glutamate. The cysteine glutamate exchange
system is ubiquitous in the brain and has a fur-
ther role in protecting against oxidative stress by
providing the rate-limiting factor for glutathione
synthesis, cysteine.'^
Glutathione is a free radical scavenger. An
excess of reactive oxygen species may cause per-
sistent reduction in cystine-glutamate exchange
in the nucleus accumbens, which may contribute
to pathological glutamate signaling. The effects of
glutamate in the nucleus accumbens are mediated
by group II metabotropic glutamate autoreceptors.
NAC increases extracellular levels of glutamate,
which stimulates group II metabotropic glutamate
receptors. Increasing glutamate in the nucleus
accumbens has been shown to reduce impulsivity
in models of compulsive drug-seeking behaviors.
McFarland and colleagues'" found in a rat model
of cocaine addiction that drug-seeking behavior
was mediated by prefrontal glutamate release into
the nucleus accumbens. In line with this, NAC pre-
vented escalation of drug intake and behavioral
sensitization in an animal model of cocaine addic-
tion.'^ Further, group II metabotropic glutamate
receptor agonists inhibited the reinstatement of
cocaine- or heroin-seeking behavior, suggesting
that this effect is mediated via group II metabo-
tropic receptors.'^'' Baker and colleagues'^ have
also demonstrated that re-instatement of drug
seeking behavior can be prevented by stimulating
cysteine glutamate exchange by NAC in a cocaine
model of addiction. Similarly, Zhou and Kalivas'^
showed that NAC blocks heroin-induced reinstate-
ment behaviour and cue responsivity, suggesting
that this mechanism plays an important role in the
reward circuitry in addictive states. Consequently,
NAC treatment may be able to restore extracellular
glutamate in the nucleus accumbens, which may
inhibit compulsive behaviors.'
There is clinical data that supports this hypoth-
esis. Mardikian and colleagues' showed that
NAC reduced cocaine use in an outpatient cohort
and there was a suggestion of greater utility of
higher doses (2,400 mg and 3,600 mg) than lower
(1,200 mg) doses. LaRowe and colleagues^ sim-
ilarly found that NAC was superior to placebo
for reducing ratings of desire to use cocaine
and reduction in responsivity to cocaine cues in
people with cocaine dependence. Grant and col-
leagues' found that NAC was superior to placebo
for symptom reduction in pathological gambling,
suggesting a key mediating role of glutamate in
non-pharmacological addictions and of NAC in
the remediation of such behavior.
In addition to impacting upon impulsivity and
addictive cues, NAC may also vary other responses
through glutathione. In animal models it has been
shown that distinct signaling pathways modulate
glutathione metabolism contingent upon whether
cortical neurons are stressed or unstressed.^"
CNS Spectr 14:7 359 July 2009
Case Report
CONCLUSION
The exact mechanism of action of NAC in these
three cases, via a direct pathway or via an effect
on stress and anxiety, remains to be elucidated.
However, a potential role of NAC in nail-biting
is suggested. Trials examining this condition as
well as related disorders in the obsessive-com-
pulsive spectrum may be valuable and this is of
particular importance as effective treatments are
not currently available. If replicated, these cases
implicate additional mechanisms in the patho-
physiology of such disorders, including the role
of glutamate and cysteine-glutamate exchange,
as well as oxidative stress. CNS
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